Table 2.
Treatment group | n | Adjusted mean | SE | Difference vs placebo
|
||||
---|---|---|---|---|---|---|---|---|
Mean | SE | Order of test | Adjusted 95% CI | Adjusted P-value | ||||
Placebo | 186 | −13.9 | 0.77 | – | – | – | – | – |
BUP150 | 190 | −14.4 | 0.77 | −0.5 | 1.00 | 1 | −2.7, 1.7 | 0.853 |
BUP300 | 188 | −12.9 | 0.76 | 1.0 | 1.00 | 2 | N/A | N/A |
Notes: CIs and the adjusted P-values were based on Dunnett’s step-down procedure. The statistical model included treatment group, region (country), and baseline value as explanatory variables. Since the first comparison (placebo vs BUP150) failed to show significance, the second comparison (placebo vs BUP300) was not performed, in order to control type I error rate.
Abbreviations: BUP150, bupropion SR 150 mg/day (once daily); BUP300, bupropion SR 150 mg/day (twice daily); CI, confidence interval; ITT–LOCF, intent-to-treat, last observation carried forward; MADRS, Montgomery–Åsberg Depression Rating Scale; N/A, not applicable; SE, standard error; SR, sustained release; n, number; vs, versus.